Caris Validates AI MGMT Signature in 5,841 GBM Patients
Caris Life Sciences validated an AI signature inferring MGMT methylation from NGS in 5,841 glioblastoma patients, achieving high concordance with pyrosequencing and improved survival stratification across MGMT subgroups. Integrated into its MI Cancer Seek assay without extra tissue, this signature could expand GBM diagnostic adoption and drive revenue.
1. AI-Driven MGMT Methylation Signature Developed
Caris developed an AI-derived model using Whole Exome and Transcriptome Sequencing data and clinical inputs to infer MGMT promoter methylation in glioblastoma, targeting temozolomide therapy selection without requiring extra tissue samples.
2. Peer-Reviewed Validation in 9,241 GBM Patients
In a validation involving 5,841 retrospective and over 3,400 prospective GBM cases, the signature achieved high concordance with pyrosequencing and effectively stratified overall survival across MGMT-defined subgroups, demonstrating improved prognostic precision.
3. Integration into MI Cancer Seek Assay
The AI signature is available via the Caris Molecular Tumor Board Report and MI Cancer Seek assay at no extra tissue or workflow change, streamlining clinical integration for GBM profiling.
4. Commercial and Clinical Implications
By enhancing predictive accuracy for temozolomide benefit, Caris could drive broader adoption of its precision oncology platform, potentially boosting diagnostic volumes and revenue in the GBM market.